Circulating tumor DNA (ctDNA) research in cervical and head and neck cancers
Our research explores the potential of circulating tumor DNA (ctDNA) as a non-invasive biomarker for monitoring treatment response and detecting minimal residual disease in patients with cervical and head and neck cancers.
By analyzing ctDNA before, during, and after therapy, we aim to identify molecular signatures associated with early relapse, resistance, and long-term outcomes. This work is especially critical in low-resource settings, where access to imaging and biopsy can be limited. Through this research, we strive to personalize cancer care, improve patient outcomes, and inform future clinical trial design.